Abstract
Since the beginning of the COVID-19 pandemic, the development of effective vaccines against this pathogen has been a priority for the scientific community. Several strategies have been developed including vaccines based on recombinant viral protein fragments. The receptor-binding domain (RBD) in the S1 subunit of S protein has been considered one of the main targets of neutralizing antibodies. In this study we assess the potential of a vaccine formulation based on the recombinant RBD domain of SARS-CoV-2 expressed in the thermophilic filamentous fungal strain Thermothelomyces heterothallica and the hepatitis B virus (HBV) core protein. Functional humoral and cellular immune responses were detected in mice. To our knowledge, this is the first report on the immune evaluation of a biomedical product obtained in the fungal strain T. heterothallica. These results together with the intrinsic advantages of this expression platform support its use for the development of biotechnology products for medical purpose.
Keywords: C1; COVID; Immunogenicity; Protein; SARS CoV-2; Vaccine.
【저자키워드】 SARS CoV-2, immunogenicity, vaccine., COVID, Protein, C1, 【초록키워드】 SARS CoV-2, SARS-CoV-2, Vaccine, immunogenicity, S protein, Neutralizing antibodies, Cellular immune response, knowledge, COVID-19 pandemic, immune, HBV, Viral, Receptor-binding domain, pathogen, mice, RBD, immune responses, hepatitis B, target, Scientific community, expression, platform, fungal, Hepatitis B virus, S1 subunit, humoral, RBD domain, core protein, Support, Viral protein, SARS CoV, domain, priority, Effective vaccines, intrinsic, the S1 subunit, expressed, effective vaccine, 【제목키워드】 SARS-CoV-2, fungal, domain, functional immune response, expressed, induce,